Currently Viewing:
Evidence-Based Oncology June 2016
So Many Metrics, Yet So Little Known About Quality and Value in Cancer Care
Joseph Alvarnas, MD
Partnering With Patients to Rapidly Develop a Quality-of-Life Measure in Mycosis Fungoides/S├ęzary Syndrome Type Cutaneous T-cell Lymphoma
Paul Wicks, PhD; Marjan Sepassi, PharmD; Gaurav Sharma, PharmD; and Margot Carlson Delogne
Using the NQF Measure Incubator to Develop Patient-Reported Outcome Performance Measures in Palliative Cancer Care
Jason Goldwater, MA, MPA; Nicole Silverman, MBA; Karen Johnson, MS; and Rachel Roiland, PhD
Quality Metrics for Oncology in a Value-Based Reimbursement World
Kim Charland, BA, RHIT, CCS, and Robin Zweifel, BS, MT (ASCP)
Currently Reading
CancerLinQ - ASCO's Rapid Learning System to Improve Quality and Personalize Insights
Robert S. Miller, MD, FACP, FASCO
A Discussion on Oncology Quality Tools: Filling in the Gaps
Surabhi Dangi-Garimella, PhD
Surmounting the Quality Chasm in Healthcare
Joseph Alvarnas, MD
Oncology Payment Reform: Payers and Providers Discuss APM and Beyond
Surabhi Dangi-Garimella, PhD
An Update on the Oncology Medical Home Model at the COA Conference
Surabhi Dangi-Garimella, PhD
Aligning Reimbursement With Quality: Are We There Yet?
Surabhi Dangi-Garimella, PhD
Industry Insight on the Challenges With Developing and Adopting Biosimilars
Surabhi Dangi-Garimella, PhD

CancerLinQ - ASCO's Rapid Learning System to Improve Quality and Personalize Insights

Robert S. Miller, MD, FACP, FASCO
CancerLinQ is a big data platform developed by the American Society of Clinical Oncology (ASCO) that aggregates clinical data from electronic health records for quality benchmarking and hypothesis generation. Such observational data can complement traditional evidence but must be used with caution.
The promotion of the highest quality cancer care has long been foundational to the mission of the American Society of Clinical Oncology (ASCO). To make this vision a reality, ASCO has been building a big data, health information technology (HIT) platform called CancerLinQ (Cancer Learning Intelligence Network for Quality), based on principles articulated by the Institute of Medicine (IOM) and others. (The division of the National Academies of Sciences, Engineering, and Medicine that focuses on health and medicine was renamed the Health and Medicine Division, from the Institute of Medicine, in 2016). 

  CancerLinQ extracts data from electronic health records (EHRs) and other sources, and using transformational data analytics, generates knowledge that can be accessed by oncologists, researchers, and patients. CancerLinQ’s primary objectives are to provide real-time quality feedback to oncologists to enable them to measure the care they render against clinical guidelines and that of their peers, to deliver personalized insights at the point of care, and to accelerate the generation of new research hypotheses by uncovering patterns in patient and tumor characteristics, therapies, and outcomes that require massive data sets and real-world evidence.

  CancerLinQ Background and History
The 2013 IOM report, Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis, identified contemporary challenges to the delivery of high-quality cancer care and specified 10 core recommendations for remediation.1 A technology-based “learning healthcare system” was identified as essential to make cancer care more evidence-based and patient-centric. The authors described a learning health system as one that uses HIT to “…continuously and automatically collect and compile from clinical practice, disease registries, clinical trials, and other sources of information, the evidence needed to deliver the best, most up-to-date care that is personalized for each patient.”2 

In a learning health system, research and practice inform each other in a virtuous cycle, one in which the findings from everyday care experiences continuously improve both practice and the discovery of new knowledge. In March 2011, the ASCO Board of Directors adopted strategic initiatives to begin the development of a rapid learning system (RLS) in oncology. Over the next 4 years, ASCO undertook a number of steps to make this RLS a reality. ASCO formed a separate Quality Department to house all of the Society’s quality programs, including CancerLinQ, and dedicated staff, volunteer committees, and external advisors were brought together to define goals and strategy and to create a business plan. A pilot of an RLS that focused on breast cancer began in 2012, using mostly open-source software, and the prototype was publicly demonstrated, albeit with limited functionality, at ASCO’s Quality Care Symposium in 2012. 

After the Board approved full build-out of the system, in 2013, ASCO commenced a rigorous process to gather requirements, leading to the release of a Request for Proposals for vendors in 2014. Also in 2014, the ASCO Board created a separate limited liability company, CancerLinQ LLC,3 as a non-profit, wholly-owned subsidiary of ASCO, with its own board and advisory committees and numerous new staff. In January 2015, ASCO announced that SAP, a German multinational corporation that makes enterprise software, was chosen to develop and deploy CancerLinQ in a co-innovation partnership with ASCO. ASCO provides the oncology subject matter expertise and controls the data, services, and products that stem from CancerLinQ, while SAP provides access to its global healthcare technical platform and engineering support to create customized tools unique to CancerLinQ’s needs. 

ASCO had previously engaged a number of early adopters from the oncology community in the United States to serve as “vanguard practices,” and between 2015 and 2016, the pace of practice engagement increased sharply. As of May 1, 2016, 37 vanguard practices had signed Business Associate Agreements with CancerLinQ, representing over 700 physicians, and nearly 600,000 patient records. Data ingestion is ongoing as new practices are added, and data connections to the EHR, established. The vanguard practice group comprises a mixture of small, community-based, single-specialty, hematology-oncology practices; larger, multisite cancer centers and integrated delivery networks; and academic medical centers. With the first release of the platform, anticipated in proximity to the ASCO Annual Meeting in Chicago, June 3-7, 2016, participating practices will have access to a full suite of features to be delivered as part of the initial version, including quality performance measures, analytic reports, and a data exploration tool known as CancerLinQ Insights (CLQI).  

CancerLinQ Data Architecture
CancerLinQ is a cloud-based solution built on SAP’s HANA, an in-memory data management and application platform providing analytics and data visualization, and hosted in a secure data center within the United States. CancerLinQ consists of a series of logical databases in the HANA Enterprise Cloud (HEC) environment, through which data flow and undergo progressive normalization and deidentification.  There are several models by which data are extracted from the EHR and flow into CancerLinQ. In the default option, the CancerLinQ engineering team deploys a third-party software agent called CancerLinQ Connect, which is installed behind the practice firewall and pulls the required data elements, both structured and unstructured, from the EHR database. A customized data file known as an HIX file is created and securely transferred to the HEC. Several “push” options are also supported, among them data warehouse extracts. Regardless of the initial data extraction methodology, incremental updates, uploaded nightly, will occur to ensure the timeliness of the clinical data in the system.

Once the data are ingested into the HEC, they flow into a data staging area or, “data lake,” which contains fully identifiable protected health information (PHI) and personably identifiable information (PII). So that the clinical quality measures can fire and the clinical concepts queried, the data are standardized via a rules engine, based on a terminologies database known as the National Cancer Institute Metathesaurus.4 The unstructured data run through a natural language processing engine for conversion to structured elements. The data land in the clinical database containing PHI and PII that can be queried by the end-user based on access privileges. Physician-users will only be able to view patient data with PHI for their own patients or, in some cases, the patients of other physicians within their practice. From there, the data then undergo deidentification via a third-party software tool and land in an analytical database for users to access the aggregated, deidentified data set. The CancerLinQ informatics team will use this database to create customized analytic reports for participating practices and other parties, pursuant to CancerLinQ data governance principles.

The end-user accesses CancerLinQ through a web browser. Product features include a set of clinical quality performance indicators based on ASCO-developed electronically specified clinical quality measures (eCQMs), discussed in the next section; the CLQI tool for customized cohort and data exploration; a patient timeline tool to visually represent oncologic milestones in the patient history; and a suite of parameterized analytic reports.

Additional data sources contemplated for CancerLinQ ingestion in future versions, include practice management systems (financial and administrative data), tumor registry data, claims data, genomic and other molecularly derived datasets, and data warehouse datasets. 

Quality Measurement and Benchmarking
The ASCO Board of Directors, from the time of its earliest strategic decisions to create CancerLinQ as a learning health system for oncology, envisioned that the primary function of the platform would be as an extension of ASCO’s quality portfolio, most notably the Quality Oncology Practice Initiative (QOPI).5 QOPI is ASCO’s signature quality assessment program for outpatient hematology-oncology practices, designed to create a culture of self-examination and improvement through periodic measurement of practice performance on established clinical quality measures, many of which are derived from ASCO’s own clinical practice guidelines. However, QOPI is a retrospective analysis, describing clinical events at least 6 months back, by which time, the opportunity to influence the care of any individual patient, has generally long passed. By comparison, CancerLinQ provides real-time assessment of practice performance on a subset of embedded eCQMs, both disease- and domain-specific, derived from the QOPI program. The eCQM results are displayed graphically in the user portal of the CancerLinQ web interface using tools in SAP HANA for measure definitions and visualization. The initial measure set, which includes eCQMs that are adapted from measures endorsed by the National Quality Forum, is shown in the TABLE below. 

Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up